Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending May 2013. The document serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility (PDMRs), and their connected persons regarding changes in their interests in GSK Ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document is strictly a regulatory disclosure of insider trading activities and does not contain financial performance data.
Material Changes
The material changes reported are specific to the shareholding positions of the following individuals on May 13, 2013:
- Sir Andrew Witty: Exercised options over 136,000 shares (2,362 and 133,638) granted in 2003. Sold 118,451 shares to cover exercise costs and retained 17,549 shares. Additionally, exercised nil-priced options under the Deferred Annual Bonus Plan, resulting in a net delivery of 19,587 shares. His shareholding requirement (4x salary) is now met at 230%.
- Mr S M Bicknell: Exercised and sold 30,000 shares granted in 2003.
- Mr D S Redfern: Exercised and sold 65,180 shares (45,000 granted in 2003; 20,180 granted in 2004).
- Ms C Thomas: Exercised and sold 65,180 shares (45,000 granted in 2003; 20,180 granted in 2004).
- Dr P J T Vallance: Exercised and sold 346,840 shares across multiple grants from 2006 to 2010.
- Mrs V A Whyte: Exercised and sold 7,800 shares granted in 2003.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of share transactions.
Investor Verification Checklist
- Verify the total number of shares sold versus retained by Sir Andrew Witty to confirm compliance with the 4x salary holding requirement.
- Confirm the exercise prices (ranging from £11.23 to £14.93) against the sale prices (approximately £16.77 to £16.89) to calculate realized gains for each executive.
- Review the specific grant dates (2003–2010) to understand the vesting periods and tenure of the options exercised.
- Check subsequent filings for any changes in the shareholding percentages of these PDMRs following these transactions.